SCHEMBL7018328

SCHEMBL7018328

CC(C)(C)OC(=O)N1CC(C#N)C(=O)C1(C)C

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CTSK P43235 3/20 0.36
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35
KMT2A Q03164 1/20 0.35
AR P10275 2/20 0.34
BUB1 O43683 1/20 0.33
DDB1 Q16531 1/20 0.33
CRBN Q96SW2 1/20 0.33
GRIN2B Q13224 1/20 0.33
GRIN2C Q14957 1/20 0.33
NR1H2 P55055 1/20 0.33
DPP4 P27487 1/20 0.32
KDM4E B2RXH2 1/20 0.32
CHRM2 P08172 1/20 0.32
CHRM1 P11229 1/20 0.32
CHRM3 P20309 1/20 0.32
GPR119 Q8TDV5 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17878691 0.84 GRIN2B (0.37) CTSKMEN1ALDH1A1MAPTKMT2A
SCHEMBL1835211 0.75 PDE4B (0.37) ALDH1A1BUB1DDB1CRBNNR1H2
SCHEMBL7014654 0.74 DDB1 (0.33) MAPTBUB1DDB1CRBNGRIN2B
SCHEMBL625040 0.72 MAPT (0.43) CTSKMEN1ALDH1A1MAPTKMT2A
SCHEMBL24203906 0.69 USP2 (0.38) MEN1ALDH1A1MAPTKMT2ADDB1
SCHEMBL22438554 0.69 AR (0.38) CTSKMEN1ALDH1A1MAPTKMT2A
SCHEMBL22438553 0.69 AR (0.38) CTSKMEN1ALDH1A1MAPTKMT2A
SCHEMBL22438551 0.69 AR (0.38) CTSKMEN1ALDH1A1MAPTKMT2A
SCHEMBL1290235 0.69 MAPT (0.46) CTSKMEN1ALDH1A1MAPTKMT2A
SCHEMBL17536013 0.68 CHRM2 (0.39) ALDH1A1MAPTBUB1NR1H2CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3773563-B1 PRODRUGS OF FUSED-BICYCLIC C5AR ANTAGONISTS CHEMOCENTRYX INC (US) 2024-10-16 EP disclosed
CN-111954525-B Prodrugs of fused bicyclic C5aR antagonists 凯莫森特里克斯股份有限公司 2023-12-26 CN disclosed
CN-111788184-B Diaryl substituted 5, 5-fused ring compounds useful as C5aR inhibitors 凯莫森特里克斯股份有限公司 2023-12-22 CN disclosed
US-11780853-B2 Substituted N-pyrimidin-4-yl-3-aminopyrrolo[3,4-C]pyrazoles as protein kinase C inhibitors PFIZER INC. (US) 2023-10-10 US disclosed
CN-115073471-B Pyrazolo tetrahydropyrrole derivative, preparation method and application thereof in medicine 沈阳药科大学 2023-03-21 CN disclosed
US-11608336-B2 Prodrugs of fused-bicyclic C5aR antagonists CHEMOCENTRYX, INC. (US) 2023-03-21 US disclosed
CN-111032658-B 5-5 fused rings as C5a inhibitors 凯莫森特里克斯股份有限公司 2022-12-20 CN disclosed
EP-3630774-B1 5-5 FUSED RINGS AS C5A INHIBITORS CHEMOCENTRYX INC (US) 2022-11-23 EP disclosed
US-11485737-B2 Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors CHEMOCENTRYX, INC. (US) 2022-11-01 US disclosed
US-11479553-B2 5-5 fused rings as C5a inhibitors CHEMOCENTRYX, INC. (US) 2022-10-25 US disclosed
US-9403835-B2 Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators ARES TRADING S.A. (CH) 2016-08-02 US disclosed
US-20150099743-A1 NOVEL N-PYRIMIDIN-4-YL-3-AMINO-PYRROLO[3,4-C]PYRAZOLE DERIVATIVES AS PKC KINASE INHIBITORS PFIZER INC. 2015-04-09 US disclosed
US-8877761-B2 N-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazole derivatives as PKC kinase inhibitors PFIZER INC. (US) 2014-11-04 US disclosed
EP-2794608-A1 TETRAAZA-CYCLOPENTA[A]INDENYL AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS Merck Patent GmbH (DE) 2014-10-29 EP disclosed
EP-2674434-A1 Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators ARES TRADING S.A. (CH) 2013-12-18 EP disclosed
WO-2013091773-A1 TETRAAZA-CYCLOPENTA[A]INDENYL AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS MERCK PATENT GMBH (DE) 2013-06-27 WO disclosed
US-20120202809-A1 NOVEL N-PYRIMIDIN-4-YL-3-AMINO-PYRROLO[3,4-C]PYRAZOLE DERIVATIVES AS PKC KINASE INHIBITORS PFIZER INC. 2012-08-09 US disclosed
US-8183255-B2 N-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazole derivatives as PKC kinase inhibitors PFIZER, INC. (US) 2012-05-22 US disclosed
US-20100130501-A1 NOVEL 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H, 6H) CARBALDEHYDE DERIVATIVES PFIZER INC. 2010-05-27 US disclosed
WO-2008096260-A1 3-AMINO-PYRROLO[3,4-C] PYRAZOLE- 5 (1H, 4H, 6H) CARBALDEHYDE DERIVATIVES AS PKC INHIBITORS PFIZER INC. (US) 2008-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11608336-B2 Prodrugs of fused-bicyclic C5aR antagonists C5AR2, C5AR1, C3AR1 CTSK 1208/4885MEN1 2135/4885ALDH1A1 2620/4885
US-11780853-B2 Substituted N-pyrimidin-4-yl-3-aminopyrrolo[3,4-C]pyrazoles as protein kinase C inhibitors PRKCB, PRKCA, PRKCQ CTSK 1266/4885MEN1 3700/4885ALDH1A1 2786/4885
US-11479553-B2 5-5 fused rings as C5a inhibitors C5AR1, C5AR2, C3AR1 CTSK 1014/4885MEN1 1902/4885ALDH1A1 3141/4885
US-11485737-B2 Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors C5AR1, C5AR2, C3AR1 CTSK 804/4885MEN1 1315/4885ALDH1A1 2995/4885
US-20100130501-A1 NOVEL 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H, 6H) CARBALDEHYDE DERIVATIVES DPP3, IAPP, GPR119 CTSK 2716/4885MEN1 3312/4885ALDH1A1 542/4885
US-20120202809-A1 NOVEL N-PYRIMIDIN-4-YL-3-AMINO-PYRROLO[3,4-C]PYRAZOLE DERIVATIVES AS PKC KINASE INHIBITORS PRKCB, PRKCA, PRKCE CTSK 1771/4885MEN1 3697/4885ALDH1A1 3817/4885
US-20150099743-A1 NOVEL N-PYRIMIDIN-4-YL-3-AMINO-PYRROLO[3,4-C]PYRAZOLE DERIVATIVES AS PKC KINASE INHIBITORS PRKCB, PRKCA, PRKCQ CTSK 2045/4885MEN1 3355/4885ALDH1A1 3650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.